Related Experiment Video
Updated: Apr 23, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?
Rozenn Quarck1, Marion Delcroix2
1Dept of Clinical and Experimental Medicine, Respiratory Division, KU Leuven - University of Leuven, Leuven, Belgium Dept of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium rozenn.quarck@med.kuleuven.be.
No abstract available in PubMed .
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Embolism III: Nursing Management
Venous Thrombosis III: Interprofessional Care
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

